中国好声音：历届ASCO，AACR和ESMO肺癌领域大会发言汇总

● 中国好声音 ●

●●●The Voice of China●●●

中国肺癌领域2008-2020三大国际顶级肿瘤学会议大会发言共计31项（其中ASCO 9项，AACR 7项，ESMO 15项）

中国肺癌

ASCO大会发言

2008ASCO: Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small-cell lung cancer  于金明  山东肿瘤医院

J.M. Yu

2008ASCO: Molecular Imaging with 11C-PD153035 PET/CT to EGFR-TKI in advanced non-small cell lung cancer  于金明 山东肿瘤医院

J.M. Yu

2011ASCO: Gefitinib versus placebo as maintenance therapy in patients withlocally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG0804): a multicentre, double-blind randomised phase 3 trial  张力 中山大学肿瘤防治中心

L. Zhang

2017ASCO: Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA(N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study  吴一龙 广东省人民医院

Y.L. Wu

2018ASCO: Dacomitinib(daco)versus gefitinib(gef)for first-line treatment of advanced NSCLC (ARCHER 1050) : Final overall survival (OS) analysis  莫树锦（Tony Mok）香港中文大学

T.S.K. Mok

2020ASCO: First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332)  王晓珊  四川省人民医院

X.S. Wang

2020ASCO: Different response to ALK inhibitors in EML4-ALK positive mediastinal cancer of unknown primary  胡春宏  中南大学湘雅二院

C.H Hu

2020ASCO: Utilizing phenotypic characteristics of metastatic brain tumors to predict the probablity of circulating tumor DNA detection from cerebrospinal fluid  陈丽昆  中山大学肿瘤防治中心

L.K. Chen

2020ASCO: CTONG1104: Adjuvant gefitinib verus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial 吴一龙 广东省人民医院

Y.L. Wu

AACR大会发言

2018AACR: Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: Results of the Phase 3 CheckMate 078 Study   吴一龙 广东省人民医院

Y.L. Wu

2019AACR: Preliminary efficacy and safety results of savolitinib treating patients with PSC and other NSCLC harboring MET exon 14 skipping mutations (NCT02897479)  陆舜  上海交通大学附属胸科医院

S. Lu

2019AACR: Tumor-derived cell-free DNA from bronchoalveolar lavage fluid (BALF): A potential liquid biopsy analysis in lung cancer patients  张新  复旦大学附属中山医院

X. Zhang

2020AACR: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations   吴一龙 广东省人民医院

Y.L. Wu

2020AACR: Almonertinib (HS-10296) for central nervous system metastases in pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer data from APOLLO study  陆舜  上海交通大学附属胸科医院

S. Lu

2020AACR: Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicencer, two-stage,phase 2 trial  王洁  中国医学科学院肿瘤医院

J. Wang

2020AACR: The experience of treating patients with cancer during the COVID-19 pandemic in China  张莉  华中科技大学同济医学院附属同济医院

L.Zhang

ESMO大会发言

2010ESMO: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,randomised, phase 3 study 周彩存 同济大学附属肺科医院

C.C. Zhou

2012ESMO: Biomarker Analyses and Overall Survival (OS) from the Randomized, Placebo-Controlled, Phase 3, Fastact-2 Study of Intercalated Erlotinib with First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC) 莫树锦（Tony Mok）  香港中文大学

T.S.K. Mok

2014ESMO: Impact of Harvested Lymph Nodes Count on Staging and Survival at Radical Resection for Non-Small Cell Lung Cancer: a Minimum of 14 Lymph Nodes Should Be Sampled  梁文华  广州医科大学附属第一医院

W.H. Liang

2014ESMO: EGFR Mutation and Survival Outcomes in Patients with Completely Resected Lung Adenocarcinoma-a Multiple Centers, Non-Interventional Study (Ican Trial)  吴一龙 广东省人民医院

Y.L. Wu

2014ESMO:  Clinical Value of Circulating Tumor Cells in Monitoring Treatment Response in Chinese Patients with Small Cell Lung Cancer  程颖 吉林省肿瘤医院

Y. Cheng

2015ESMO: Recombinant Human Endostatin Combined with Chemotherapy for Malignant Pleural Effusion  胡艳萍 湖北省肿瘤医院

Y.P. Hu

2016ESMO: Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvantchemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC final results of CSLC0501  吴一龙 广东省人民医院

Y.L. Wu

2016ESMO: First-in-human study of AC0010, a novel irreversible, mutant-selective EGFR inhibitor in patients with 1st generation EGFR TKI-resistant non-small cell lung cancer (NSCLC)  张力  中山大学肿瘤防治中心

L. Zhang

2018ESMO: CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study  钟文昭  广东省人民医院

W.Z. Zhong

2018ESMO: Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth fact or receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)  吴一龙 广东省人民医院

Y.L. Wu

2018ESMO: Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naive ALK+ advanced NSCLC  周彩存 同济大学附属肺科医院

C.C. Zhou

2019ESMO: Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)  程颖 吉林省肿瘤医院

Y. Cheng

2019ESMO: CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC 周清 广东省人民医院

Q. Zhou

2019ESMO: Integrated Genomic Mutation and DNA Methylation Analyses of Non-small Cell Lung Cancer Patients with Brain Metastases  范云  中国科学院大学附属医院（浙江省肿瘤医院）

Y.J. Xu

2020ESMO: A Phase 1b Study of TQB2450 in Combination with Anlotinib in Patients with Advanced Solid Tumor  程颖  吉林省肿瘤医院

Y. Cheng